662 results match your criteria IAPAC Monthly[Journal]
Lancet 2017 07;390(10092):341-343
International Association of Providers of AIDS Care, Washington DC 20036, USA.
J Int Assoc Provid AIDS Care 2016 07;15(4):273-5
International Association of Providers of AIDS Care, Washington, DC, USA
Lancet 2016 Jan;387(10013):27
International Association of Providers of AIDS Care, Washington DC 20036, USA; Wits Reproductive Health and HIV Institute, University of the Witwatersrand, Johannesburg, South Africa.
J Int Assoc Provid AIDS Care 2016 Mar-Apr;15(2):91-100. Epub 2015 Dec 28.
International Association of Providers of AIDS Care, Washington DC, USA.
Unlabelled: : Achieving the 90-90-90 targets by 2020 requires increased focus, resources, and efficiency to provide earlier access to antiretroviral therapy (ART).
Methods: We used 2009 to 2013 National AIDS Spending Assessment data to assess HIV care and treatment spending in 38 high-burden, low- and middle-income countries (LMICs).
Results: In 2013, 23 of the 38 high-burden countries spent less than 50% of total HIV spending on care and treatment. Read More
J Int Assoc Provid AIDS Care 2015 Nov-Dec;14 Suppl 1:S3-S34. Epub 2015 Nov 2.
Background: An estimated 50% of people living with HIV (PLHIV) globally are unaware of their status. Among those who know their HIV status, many do not receive antiretroviral therapy (ART) in a timely manner, fail to remain engaged in care, or do not achieve sustained viral suppression. Barriers across the HIV care continuum prevent PLHIV from achieving the therapeutic and preventive effects of ART. Read More
Lancet Infect Dis 2015 Dec 27;15(12):1492-6. Epub 2015 Oct 27.
International Association of Providers of AIDS Care (IAPAC), Washington, DC, USA.
Antiretroviral therapy (ART) is the main intervention needed to reduce morbidity and mortality and to prevent tuberculosis in adults living with HIV. However, in most resource-limited countries, especially in sub-Saharan Africa, ART is started too late to have an effect with substantial early morbidity and mortality, and in high tuberculosis burden settings ART does not reduce the tuberculosis risk to that reported in individuals not infected with HIV. Co-trimoxazole preventive therapy started before or with ART, irrespective of CD4 cell count, reduces morbidity and mortality with benefits that continue indefinitely. Read More
J Int Assoc Provid AIDS Care 2015 Nov-Dec;14(6):536-43. Epub 2015 Aug 20.
Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
The authors sought to assess whether viral load (VL) monitoring frequency was associated with differential rates of virologic failure (VF) among HIV Outpatient Study (HOPS) participants seen during 1999 to 2013, who had maintained VL <50 copies/mL, CD4 counts ≥300 cells/mm(3), and been prescribed a stable combination antiretroviral regimen for at least 2 years. The authors required VL and CD4 testing to have occurred regularly for the entire 2-year period. The authors assessed rates of VF comparing patients who maintained a frequent VL testing (≥3 VLs) to those who shifted to a less frequent schedule (2 VL) after the 2-year period. Read More
Lancet Infect Dis 2015 Jul;15(7):833-9
Hubert Department of Global Health, Rollins School of Public Health of Emory University, Atlanta, GA, USA; Emory University Center for AIDS Research, Atlanta, GA, USA.
Combination antiretroviral therapy (ART), also known as highly active antiretroviral therapy, provides clinical and immunological benefits for people living with HIV and is an effective strategy to prevent HIV transmission at the individual level. Early initiation of ART as part of a test and treat approach might decrease HIV transmission at the population level, but to do so the HIV continuum of care, from diagnosis to viral suppression, should be optimised. Access to ART has improved greatly in Latin America, and about 600,000 people are on treatment. Read More
Lancet Infect Dis 2014 Jan 27;14(1):5-6. Epub 2013 Sep 27.
International Association of Providers of AIDS Care, Washington, DC 20005, USA; Josef Korbel School of International Studies, University of Denver, Denver, CO, USA. Electronic address:
J Int Assoc Provid AIDS Care 2013 May-Jun;12(3):208-16
Harvard University, Boston, MA, USA.
In the context of emerging evidence related to preexposure prophylaxis and HIV treatment as prevention, an evidence summit was held in mid-2012 to discuss the current state of the science and to provide a platform for consensus building around whether and how these prevention strategies might be implemented globally. Health care providers, researchers, policy makers, people living with HIV/AIDS, and representatives of government authorities, donor agencies, pharmaceutical companies, advocacy organizations, and professional associations attended from 52 countries. An international advisory committee was convened to identify key messages and recommendations based upon the data presented and discussed at the summit. Read More
J Int Assoc Provid AIDS Care 2013 Mar-Apr;12(2):79-83
Center for Health, Intervention and Prevention (CHIP), University of Connecticut, Storrs, CT 06269, USA.
High, persistent levels of antiretroviral therapy (ART) adherence are generally required to achieve sustained virologic suppression. Recently published global guidelines on entry into and retention in care and ART adherence include recommendations for monitoring and supporting ART adherence as a standard part of HIV clinical management. Several tools to facilitate the dissemination and implementation of these evidence-based guidelines are under development. Read More
Int J Pediatr Otorhinolaryngol 2012 Jul 28;76(7):1065-6. Epub 2012 Apr 28.
Ali Yavar Jung National Institute for the Hearing Handicapped, Eastern Regional Centre, B.T. Road, Bon Hooghly, Kolkata 700090, India.
American Speech-Language Association (ASHA) and the International Association of Physicians in AIDS Care (IAPAC) reported that speech-language and hearing disorders that occur as a direct or indirect consequence of HIV-infection are so common. However there has been little research into the nature and onset of such communication disorders in children living with HIV. Therefore the purpose of the study is to understand about the nature and onset of audiological and speech-language disorders of a group of children with HIV for the better management. Read More
J Int Assoc Physicians AIDS Care (Chic) 2009 Jan-Feb;8(1):13-20. Epub 2009 Feb 11.
J Int Assoc Physicians AIDS Care (Chic) 2008 Jul-Aug;7(4):160-77. Epub 2008 Jul 14.
International Association of Physicians in AIDS Care (IAPAC), Chicago, IL, USA.
Background: Antiretroviral therapy (ART) has reached millions of HIV-infected patients worldwide, however very little is known about their perceptions about HIV disease and its treatment. The AIDS Treatment for Life International Survey (ATLIS) is the largest sampling of patient perceptions about HIV disease and its treatment, as well as their behaviors, including HIV status disclosure and ART adherence.
Methods: The International Association of Physicians in AIDS Care (IAPAC) and its survey vendor, Ipsos Insight Health, conducted a convenience-sample survey of 2555 treated and untreated HIV-infected adults recruited by diverse means from 6 regions: North America, Latin America, the Caribbean, Europe, Asia/Pacific, and sub-Saharan Africa. Read More
IAPAC Mon 2007 Feb;13(2):55
IAPAC Mon 2007 Feb;13(2):39-40
IAPAC Mon 2007 Feb;13(2):38-9
IAPAC Mon 2007 Jan;13(1):27
IAPAC Mon 2007 Jan;13(1):12
IAPAC Mon 2007 Jan;13(1):11-2
IAPAC Mon 2007 Jan;13(1):10-1
IAPAC Mon 2007 Jan;13(1):4-6
IAPAC Mon 2006 Dec;12(12):446
IAPAC Mon 2006 Dec;12(12):424-35
IAPAC Mon 2006 Dec;12(12):419-20
IAPAC Mon 2006 Dec;12(12):416-7
IAPAC Mon 2006 Oct;12(10):375-6
IAPAC Mon 2006 Oct;12(10):354-65
After the marathon-like challenge presented by the 16th International AIDS Conference held in Toronto a month prior--a challenge that tested the stamina of even the youngest and fittest of conference-goers--the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), held September 27-30, 2006, in San Francisco, was a welcome relief in its staid and singular focus on the presentation of data offering insights into the challenges a variety of patients and their physicians are facing in the second decade of highly active antiretroviral therapy (HAART), as well as reviews of how to make optimal use of antiretroviral regimens constructed from within the existing HAART armamentarium. The big news at this year's ICAAC, however, was on the antiretroviral pipeline, with previews of how a new generation of drugs may help make the difference between life and death for countless millions of men, women, and children living with HIV/AIDS. Read More
IAPAC Mon 2006 Oct;12(10):342
IAPAC Mon 2006 Oct;12(10):340-2
IAPAC Mon 2006 Nov;12(11):403-4
IAPAC Mon 2006 Nov;12(11):394-9
IAPAC Mon 2006 Nov;12(11):390
IAPAC Mon 2006 Nov;12(11):388-9
IAPAC Mon 2006 Sep;12(9):329
IAPAC Mon 2006 Sep;12(9):302-17
IAPAC Mon 2006 Sep;12(9):294
IAPAC Mon 2006 Sep;12(9):292-3
IAPAC Mon 2006 Aug;12(8):276
IAPAC Mon 2006 Aug;12(8):270
Federal University of Rio de Janeiro, Brazil.
IAPAC Mon 2006 Aug;12(8):262-3
IAPAC Mon 2006 Aug;12(8):256-7
IAPAC Mon 2006 Feb;12(2):50-1
IAPAC Mon 2006 Jan;12(1)
IAPAC Mon 2006 May;12(5):157
IAPAC Mon 2006 May;12(5):150-5
IAPAC Mon 2006 May;12(5):148-9
IAPAC Mon 2006 May;12(5):144-6
IAPAC Mon 2006 Feb;12(2):50
IAPAC Mon 2006 Feb;12(2):42-5
The use of HIV testing and information about one's serostatus as an HIV prevention tool remains a complex and controversial area of debate, largely due to issues of trust: trust in the confidentiality of information, trust that health care providers will not test without consent, and trust that partners are telling the truth about their status. Read More